TY - JOUR
T1 - Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
AU - Bacigalupo, Andrea
AU - Dominietto, Alida
AU - Pozzi, Sarah
AU - Miglino, Maurizio
AU - Albarracin, Flavio
AU - Piaggio, Giovanna
AU - Bertolotti, Francesca
PY - 2008/6
Y1 - 2008/6
N2 - Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p
AB - Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p
KW - Acute lymphoid leukemia
KW - Acute myeloid leukemia
KW - Allogeneic hematopoietic stem cell transplantation
KW - Donor lymphocyte infusion
KW - Minimal residual disease
UR - http://www.scopus.com/inward/record.url?scp=55949084019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55949084019&partnerID=8YFLogxK
U2 - 10.1590/S1516-84842008000600011
DO - 10.1590/S1516-84842008000600011
M3 - Article
AN - SCOPUS:55949084019
SN - 1516-8484
VL - 30
SP - 42
EP - 44
JO - Revista Brasileira de Hematologia e Hemoterapia
JF - Revista Brasileira de Hematologia e Hemoterapia
IS - SUPPL. 2
ER -